Is Lantern Pharma Stock a Good Investment?
Lantern Pharma Investment Advice | LTRN |
- Examine Lantern Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lantern Pharma's leadership team and their track record. Good management can help Lantern Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lantern Pharma's business and its evolving consumer preferences.
- Compare Lantern Pharma's performance and market position to its competitors. Analyze how Lantern Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if Lantern Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lantern Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lantern Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lantern Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lantern Pharma Stock
Researching Lantern Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.25. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lantern Pharma recorded a loss per share of 1.78. The entity had not issued any dividends in recent years.
To determine if Lantern Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lantern Pharma's research are outlined below:
| Lantern Pharma generated a negative expected return over the last 90 days | |
| Lantern Pharma has high historical volatility and very poor performance | |
| Net Loss for the year was (15.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lantern Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: LTRN Stock Earnings Lantern Pharma Misses EPS for Q1 2024 - MSN |
Lantern Pharma Quarterly Cash And Short Term Investments |
|
Lantern Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lantern Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lantern Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Lantern Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Lantern Pharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-03 | 2021-03-31 | -0.27 | -0.24 | 0.03 | 11 | ||
2021-07-29 | 2021-06-30 | -0.26 | -0.21 | 0.05 | 19 | ||
2020-10-29 | 2020-09-30 | -0.33 | -0.27 | 0.06 | 18 | ||
2024-05-09 | 2024-03-31 | -0.43 | -0.51 | -0.08 | 18 | ||
2022-03-10 | 2021-12-31 | -0.4 | -0.32 | 0.08 | 20 | ||
2024-08-08 | 2024-06-30 | -0.55 | -0.46 | 0.09 | 16 | ||
2022-05-03 | 2022-03-31 | -0.29 | -0.38 | -0.09 | 31 | ||
2021-11-01 | 2021-09-30 | -0.27 | -0.36 | -0.09 | 33 |
Know Lantern Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lantern Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lantern Pharma backward and forwards among themselves. Lantern Pharma's institutional investor refers to the entity that pools money to purchase Lantern Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perigon Wealth Management, Llc | 2024-09-30 | 28.9 K | Sigma Planning Corp | 2024-09-30 | 28.6 K | Horizon Asset Management Inc/ny | 2024-09-30 | 27.6 K | Bank Of New York Mellon Corp | 2024-06-30 | 26.5 K | Ubs Group Ag | 2024-06-30 | 25.5 K | State Street Corp | 2024-06-30 | 23.7 K | Tocqueville Asset Management L.p. | 2024-09-30 | 17 K | Meridian Wealth Management, Llc | 2024-06-30 | 14.9 K | Northern Trust Corp | 2024-09-30 | 12.8 K | Vanguard Group Inc | 2024-09-30 | 363.7 K | Cm Management, Llc | 2024-09-30 | 185 K |
Lantern Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.76 M.Market Cap |
|
Lantern Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.38) | |
| Return On Capital Employed | (0.44) | (0.41) | |
| Return On Assets | (0.37) | (0.38) | |
| Return On Equity | (0.39) | (0.37) |
Determining Lantern Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Lantern Pharma is a good buy. For example, gross profit margin measures Lantern Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lantern Pharma's profitability and make more informed investment decisions.
Evaluate Lantern Pharma's management efficiency
Lantern Pharma has return on total asset (ROA) of (0.2807) % which means that it has lost $0.2807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4482) %, meaning that it created substantial loss on money invested by shareholders. Lantern Pharma's management efficiency ratios could be used to measure how well Lantern Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Lantern Pharma's Non Current Assets Total are very stable compared to the past year. As of the 27th of November 2024, Non Currrent Assets Other is likely to grow to about 47.8 K, while Total Assets are likely to drop about 36.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.77 | 2.50 | |
| Tangible Book Value Per Share | 3.77 | 2.50 | |
| Enterprise Value Over EBITDA | (1.56) | (1.64) | |
| Price Book Value Ratio | 1.13 | 1.19 | |
| Enterprise Value Multiple | (1.56) | (1.64) | |
| Price Fair Value | 1.13 | 1.19 | |
| Enterprise Value | 24.7 M | 23.5 M |
The strategic initiatives led by Lantern Pharma's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.567 |
Basic technical analysis of Lantern Stock
As of the 27th of November, Lantern Pharma secures the Risk Adjusted Performance of (0.08), standard deviation of 4.31, and Mean Deviation of 3.21. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lantern Pharma, as well as the relationship between them.Lantern Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lantern Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lantern Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lantern Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lantern Pharma's Outstanding Corporate Bonds
Lantern Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lantern Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lantern bonds can be classified according to their maturity, which is the date when Lantern Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Lantern Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lantern Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.21 | |||
| Coefficient Of Variation | (851.81) | |||
| Standard Deviation | 4.31 | |||
| Variance | 18.62 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (1.19) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 23.02 | |||
| Value At Risk | (6.88) | |||
| Potential Upside | 6.07 | |||
| Skewness | 0.403 | |||
| Kurtosis | 1.35 |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 3.21 | |||
| Coefficient Of Variation | (851.81) | |||
| Standard Deviation | 4.31 | |||
| Variance | 18.62 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (1.19) | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 23.02 | |||
| Value At Risk | (6.88) | |||
| Potential Upside | 6.07 | |||
| Skewness | 0.403 | |||
| Kurtosis | 1.35 |
Consider Lantern Pharma's intraday indicators
Lantern Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lantern Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 4328.14 | |||
| Daily Balance Of Power | (0.32) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 3.16 | |||
| Day Typical Price | 3.13 | |||
| Price Action Indicator | (0.12) | |||
| Period Momentum Indicator | (0.06) |
Lantern Pharma Corporate Filings
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 26th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 24th of May 2024 Other Reports | ViewVerify | |
| 3rd of May 2024 Other Reports | ViewVerify |
Lantern Stock media impact
Far too much social signal, news, headlines, and media speculation about Lantern Pharma that are available to investors today. That information is available publicly through Lantern media outlets and privately through word of mouth or via Lantern internal channels. However, regardless of the origin, that massive amount of Lantern data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lantern Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lantern Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lantern Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lantern Pharma alpha.
Lantern Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Lantern Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lantern Pharma Corporate Management
| DVM MS | CoFounder Advisor | Profile | |
| Nicole Leber | Finance Associate | Profile | |
| MS BS | Head Operations | Profile | |
| Kishor Bhatia | Chief Consultant | Profile | |
| Marc MD | Chief Therapeutics | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Lantern Pharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.